Year in Review | Published:

Lung cancer in 2017

Giant steps and stumbling blocks

Nature Reviews Clinical Oncology volume 15, pages 7172 (2018) | Download Citation

In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued to emanate from the fields of molecularly targeted therapy and immunotherapy. In the former, new drugs with improved efficacy and reduced toxicity entered the clinic; in the latter, immune-checkpoint inhibition proved efficacious after chemoradiotherapy for stage III disease, but had disparate results in the frontline treatment of stage IV disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , , & Refining the treatment of NSCLC according to histological and molecular subtypes. Nat. Rev. Clin. Oncol. 12, 511–526 (2015).

  2. 2.

    et al. Osimertinib or platinum–pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).

  3. 3.

    et al. Osimertinib versus standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Ann. Oncol. 28 (Suppl. 5), v605–v649 (2017).

  4. 4.

    & Crizotinib. Recent Results Cancer Res. 201, 197–205 (2014).

  5. 5.

    et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int. J. Cancer 134, 1484–1494 (2014).

  6. 6.

    et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).

  7. 7.

    et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390, 29–39 (2017).

  8. 8.

    et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376, 2415–2426 (2017).

  9. 9.

    et al. Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).

  10. 10.

    et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. (2017).

Download references

Author information


  1. David F. Heigener and Martin Reck are at the Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Centre North (ARCN), German Center for Lung Research (DZL), Woehrendamm 80, Grosshansdorf, Schleswig-Holstein 22927, Germany.

    • David F. Heigener
    •  & Martin Reck


  1. Search for David F. Heigener in:

  2. Search for Martin Reck in:

Competing interests

D.F.H. and M.R. are advisory board members for, and have received honoraria for speaking and reimbursement for travel from Astra Zeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Pfizer, and Roche. Both authors have also received honoraria for speaking from Chugai and Fresenius; D.F.H. is an advisory board member for both companies, and M.R. for Chugai.

Corresponding author

Correspondence to David F. Heigener.

About this article

Publication history



Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing